ANABV AnaptysBio, Inc. Common Stock When Issued

Healthcare

$43.80+1.86%ClosedMarket Cap: $1.26B

As of 2026-05-25

Valuation

P/E (TTM)

—

PEG

—

P/B

—

P/S

—

EV/EBITDA

—

DCF Value

—

FCF Yield

—

Div Yield

—

Margins & Returns

Gross Margin

—

Operating Margin

—

Net Margin

—

ROE

—

ROA

—

ROIC

—

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.41

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.